MedTrace Logo

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.

NCT04736745 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-07-14

No results posted yet for this study

Summary

The purpose of the protocol, is to assess the safety and efficacy profile of IPN59011 compared to a placebo. IPN59011 is expected to work longer than product already marketed in the treatment of subjects with moderate to severe facial wrinkles.

Conditions

  • Moderate Upper Facial Lines
  • Severe Upper Facial Lines

Interventions

BIOLOGICAL

IPN59011

Powder and solvent for solution for injection

BIOLOGICAL

Azzalure

Powder for solution for injection

DRUG

Placebo

Powder for solution for injection

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04736745 on ClinicalTrials.gov